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ABSTRACT 
Toward the era of 2000，a strategic vision of most multinational corporations 
(MNCs) is to pursue their geographical expansion to unexplored markets. The People 
Republic of China (PRC) signifies a prime business opportunity because of its sizable 
population and rapid economic growth. 
There is no exception for pharmaceutical industry. In addition to the above 
two fundamental favorable factors, the attractiveness of the PRC is further fuelled by 
the improvement of intellectual property protection which is particularly important to 
research based pharmaceutical companies from strategic standpoint. As the threat of 
generic erosion can be delayed under the revised patent law, heavy investment to 
develop the brand is better justified for secure return. 
In terms of Michael Porter's structural analysis of competitive forces, the PRC 
pharmaceutical industry can be regarded as a four and a half star industry. The four 
stars stem from intensity of rivalry among competitors, threat of new entrants, threat 
of substitute products and bargaining power of suppliers. 
Generally speaking, the competition among the major market players is very 
keen. However, due to sizable untapped potential and rapid economic growth, the 
PRC pharmaceutical market is still very attractive and is large enough to accommodate 
every player to be a winner. 
The protectionism of government policy and heavy upfront capital investment 
, of R&D are the two key entry barriers for new multinational pharmaceutical firms. 
This provides less erratic environment for the existing players to enjoy business 
growth and investment return. 
Although Chinese herbal medicine and acupuncture are popular treatment 
methods in PRC, the trend toward western medicine is very positive because the 
training of western medicine is much faster and more systematic. Moreover, Chinese 
style treatment is generally less effective in the relief of acute diseases. Thus, the 
pressure from substitute product is not substantial. 
The bargaining power of suppliers is very small because the most valuable 
component - the compound offering therapeutic effects is made from inexpensive raw 
materials which are being sold as commodity. 
The only competitive force left less attractive is bargaining power of buyers 
because of two main reasons. Firstly, government policy protects local pharmaceutical 
firms by strongly discouraging imported finished products, and secondly, purchasing 
decisions made at distributor and pharmacist levels are usually based on price rather 
than product quality. These make extensive market penetration and attractive 
profitability relatively difficult. 
Being the world's leading pharmaceutical company, Merck ought to fully 
capitalize on this golden opportunity to establish a strong foothold in the PRC market 
to sustain its survival on a long term basis. In order to formulate a series of tailor-
made competitive strategy, the strengths and weaknesses of Merck are evaluated. The 
key competitive edge of Merck arises from its existing strong product line, as well as 
its reputation of innovative research and development of novel drugs, while the most 
critical issue that should be carefully addressed is its entry being relatively late 
compared to other major multinational pharmaceutical company. 
Apart from industry and company environment, several unique characteristics 
of the PRC market are also identified to supplement the overall analysis. This process 
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is important because differences in country system and basic value will play a 
significant role in steering the strategy. These include government policy, economic 
discrepancy, technological gap and cultural difference. 
After thorough analysis has been made, a series of competitive strategy is 
recommended. It consists of entry strategy which suggests various alternatives for the 
PRC market entry, portfolio strategy which advises the approaches for product line 
management, targeting strategy which discusses the priority territory for Merck's 
product line and alliance strategy which proposes the possible alternatives of 
partnership with local pharmaceutical firms. 
Lastly, the future of the PRC pharmaceutical market is briefly discussed. Since 
it is difficult to predict whether it will change for the better or for the worse, in order 
to compete successfully, it is crucial for Merck to proactively shape the industry to 
ensure the most positive environment for achieving its strategic goals in the PRC. The 
whole notion of strategic marketing planning is a long term and never-ending process. 
I 
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This chapter will briefly introduce the company background of Merck which 
covers the current performance and the future business challenge on a long term basis. 
This will be followed by an evaluation of the attractiveness of the People's Republic 
of China (PRC) market in the context of Merck. With the understanding of the 
company and market to be pursued, a thorough discussion on the strategic marketing 
planning of Merck in PRC will be brought up in the subsequent chapters. 
The Company Background 
Merck & Co.，Inc. (Merck), is an international, research-intensive health 
products company focusing on the discovery, development and marketing of important 
human and animal health products and specialty chemical. Among these product 
varieties, human ethical pharmaceutical products constitutes over 80% of Merck's 
business. 
The company traces its origins to Germany in 1668. Merck was established 
in the United States in 1891，began its research program in the 1930，s and rapidly 
became known for its achievement in pharmaceutical science. In 1992, Merck 
invested more than US$1 billion in research and development. 
In addition to its leading position in pharmaceutical research and development, 
Merck can also manage to perform at its best in the areas of sales achievement and 
overall management. Merck is the largest pharmaceutical company worldwide 
achieving an annual sales over US$7 billion in 1992. It has recently been announced 
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that，for the seventh consecutive year, Fortune magazine named Merck the most 
admired corporation in the United States (Reese 1993). These are the solid evidences 
of the global reputation of Merck. 
As other leading corporations regardless of which industry, Merck ought to 
expand in order to continue to grow. The commitment of new product development 
with strong R&D support is crucial. Of equal importance, geographical expansion to 
new markets is also critical in view of the slow growth of established markets like the 
United States, and Europe. Markets in the Pacific Rim are really attractive to Merck 
as they are undergoing the fastest period of economic expansion in history (Naisbitt 
and Aburdene 1990). 
Although Merck has been well established from the global perspective, it is 
rather young in the Far East which excludes Japan. While most of other 
pharmaceutical companies have already had their own subsidiaries, Merck was still 
doing business through distributors or licensees arrangement after the reorganization 
in 1987 when active sales and marketing functions started. 
Merck Sharp & Dohme (Asia) Ltd. is a subsidiary of Merck and is the regional 
office for nine markets in the Far East region, namely Hong Kong, Singapore, 
Malaysia, Taiwan, Thailand, Philippines, Korea, Indonesia and PRC. The marketing 
skill sophistication is a continuum with PRC at the least mature end because Merck 
was just involved in the giant market. 
The business in PRC has not started until 1989 when licensing agreement was 
signed with a technoventure company. The sales revenue marked less than US$1.5 
million in 1992 which was far from satisfaction. 
In view of the strategic importance of PRC market to the long term survival 
of the company, Merck is considering to change the current business arrangement to 
make a significant success in PRC through a more aggressive approach. 
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The Appeal of PRC 
Turning to the market attractiveness of PRC, the fundamental condition is its 
economic growth. Over the last decade, PRC has emerged as an important economic 
power and major trading nation. A window was opening to western trade, technology 
and investment which was an essential part of that reform. The nominal GDP 
achieved US$350 billion in 1991 and is expected to have a 5-year average growth of 
6.5% (Howarth 1992). 
Real GNP has grown by an average of almost 9% a year in the past 14 years 
(Rohwer 1992). If PRC continues to hit its growth targets, she will have matched the 
performance of Japan, Taiwan and South Korea during their fastest quarter-centuries 
of economic growth. 
Deng Xiaoping's visit to southern China in early 1992 reconfirmed the 
economic policy of reform and opening to the outside world as the road to lead China 
to strength and prosperity. The slogans, "to implement market economics of 
socialism" and "to build socialism with Chinese characteristics" are the top-down basic 
principles of the whole community. 
Furthermore, the 14th Communist Party Congress held last October signified 
strong commitment to develop favorable economic environment for investment. The 
future of China from economic perspective is fairly optimistic. 
In addition to rapid economic expansion, the PRC population marked 1.1 
billion in 1990 at an estimated growth rate of 1.2% (China Market Atlas 1992). Of 
the total population, only 300 million (26%) are urban dwellers; about 2% numbers 
22 million belong to middle to upper income group with annual income. Although 
the current middle/upper income group is very limited, the size which represents the 
latent market potential is growing with economy. 
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Besides favorable economic and demographic profile, PRC market is also 
considered to be stable politically. Despite the tragedy at Tiananmen Square, the 
economy has recovered so rapidly that it seems there is nothing which can hinder the 
growth. It is generally believed that the political situation of PRC tends to become 
more stable in the years ahead to gain the greatest economic benefits. Like the recent 
release of one of the prodemocratic students, Wang Dan, has shown a gesture of 
respecting human rights as a bargaining power for the renewal of Most Favored 
Nation (MFN). Political retrograde step should not happen again. 
With over one-fifth of the world's population, relatively stable political 
situation and an economy that is expanding at an average of more 6% each year, it is 
not questionable that PRC is potentially the world's largest marketplace. Some 
analysts even believe its emerging economies may change the conventional world 
order. 
At present, the health care in PRC is regarded as underdeveloped. It can be 
reflected from the funding of health care which accounted for only 1.1% of GNP in 
1987 (Howarth 1992) as well as from the health care spending which was marginally 
over 1% of total consumer outlays in 1988 (Shaw and Woetzel 1992). Compared to 
more advanced Asian markets like Hong Kong and Korea, the percent of health care 
spending is significantly higher which is about 6-7% (Shaw and Woetzel 1992). 
There is correlation that the better the economy, the better the health care system 
which implies that the size of pharmaceutical industry is expanding with the economy. 
Therefore, if the PRC economic growth can keep the current momentum, the 
prospect of the PRC pharmaceutical market is very promising and of strategic 
importance to multinational pharmaceutical companies. The growth of the 
pharmaceutical industry in the next decade is expected to be exponential because the 
percent of health care spending versus the total spending ought to be adjusted up to 
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match with that of advanced countries. 
Due to the rapid economic growth, consumers will naturally pursue quality 
products. This will be a catalyst, for the growth of the research-based drug industry 
in PRC. The following lists favorable factors to Merck: 
. T a n g i b l e evidence of accelerated growth of health care systems leading to better 
basic health care infrastructure. 
• Increasing degree of urbanization leading to increasing demand of modern western 
medicine 
. Product line of Merck suited to a growing middle class in PRC 
Scope and Objective 
In order to fully capitalize the market potential of PRC, a strong organization 
should be established. With the current licensee arrangement, it cannot expect any 
dramatic growth in terms of sales revenue because the conflict of interest between 
Merck and the licensee seems very significant. A strong commitment in building the 
organization is essential to capitalize on the golden opportunity to become a leading 
multinational company in PRC. Therefore, Merck should establish a direct presence 
in PRC. The objective of the study is to recommend an optimal competitive strategy 
for Merck to materialize the above long term vision. 
Structure of the Paper 
To begin with, the paper will review in the next chapter the famous model of 
business strategy defined by Michael Porter (Porter) with respect to the concept of 
industry analysis and competitive strategy (Porter 1980，1988). In addition, chapter 
II also uses two case studies to explore whether there are any unique features in the 
PRC context that should be identified in order to accomplish a thorough analysis. 
This is an essential step of the overall project because Porter's model is established 
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based upon the advanced business environment of the U.S.. There are several inherent 
characteristics that PRC possesses which may affect the process of shaping the 
competitive strategy for Merck. The following points illustrate the key differences 
between PRC and U.S.: 
• PRC is barely a developing country whereas U.S. is already a post-modern 
country. In the U.S., a lot of business norms or orders have been fairly mature. 
• PRC is a communist country but U.S. is basically a democratic country. In PRC, 
one party in sovereignty has been practised for more than forty years. 
• PRC inherits a high-context Chinese culture while U.S. originates in a low-context 
text culture (Keegan 1989). A detailed comparison of these two cultures is shown 
in Appendix I. 
. Until early 1980's when open door policy was introduced, PRC has implemented 
centrally planning economy in which the government owns most of the capital 
and makes many of the economic decisions for over thirty years. However, U.S. 
is typically running free market economy in which transactions between buyers 
and sellers take place with little or no government interference (Wonnacott and 
Wonnacott 1990). 
It then comes to chapter III with the pharmaceutical industry analysis in PRC 
based on the five competitive forces. Following thorough analysis made and lessons 
learnt from the case studies, a series of strengths/opportunities and weaknesses/threat 
are to be lined up to develop the competitive strategy for Merck in chapter IV. 
Chapter V will finally conclude with the consideration of key issues identified and 




This chapter will introduce the concept of Porter's model of industry analysis 
and its relation to the formulation of competitive strategy. In addition, it will use two 
leading MNCs which have noticeably demonstrated a success in PRC to appraise the 
validity of Porter's model in PRC. Based on the framework, the possibility of Merck 
to compete successfully in PRC, the core question for this study，can be answered. 
Michael Porter's Model 
Michael Porter is famous for the theory of how competitive forces shape 
strategy, the essence of strategy formulation is coping with competition. In the fight 
of market share, competition is not manifested only in the other players. From a 
broader perspective, competition in an industry is rooted in its underlying economics, 
competitive forces exist that go well beyond the established combatants in a particular 
industry. Customers, suppliers, potential entrants and substitute products are all 
competitors that may be more or less prominent or active depending on the industry. 
The state of competition in an industry depends on five basic forces which are 
diagrammed in Appendix II. They are threat of new entrants, bargaining power of 
customers, bargaining power of suppliers, threat of substitute products, and rivalry 
among industry competitors. The collective strength of these forces determines the 
ultimate profit potential of an industry. It ranges from intense in industries like 
plastic, steel and paper, where no company earns outstanding returns on investment, 
to mild in industries like cosmetics, oil field services and equipment, and toiletries, 
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where there are relatively high returns (Porter 1980). 
Once the forces affecting competition in an industry and their underlying 
causes have been diagnosed, the firm is in a position to identify its strengths and 
weaknesses. The crucial strengths and weaknesses from a strategic standpoint are the 
company's posture vis-a-vis the underlying causes of each forces. Where does it stand 
against substitutes? Against the source of entry barriers? In coping with rivalry from 
established competitors? 
An effective competitive strategy takes offensive or defensive action in order 
to create a defendable position against the five competitive forces. The possible 
approaches include: 
• Positioning the firm so that its capabilities provide the best defense against the 
competitive forces; 
. Influencing the balance of the forces through strategic moves, thereby improving 
the firm's position; or 
. Anticipating shifts in the factors underlying the forces and responding to them, 
thereby exploiting change by choosing a strategy appropriate for the new 
competitive balance before rivals recognize it (Porter 1980，1989). 
Evaluation of Porter's Model 
There is no doubt that Porter's model is very comprehensive in the structural 
analysis of a particular industry. However, the concept of this model was developed 
with reference to the U.S. environment which is basically a free market economy 
society and practises western culture. 
If fundamental differences are existent in a society outside the U.S., some 
unique factors which might not be obvious in Porter's model should be carefully 
considered in the process of strategic planning. In view of this need, two in-depth 
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interviews were conducted to identify those unique features in the PRC market. The 
two companies can be regarded as fairly successful MNCs in PRC and they are 
involved in different industries with one hi-tech computer vendor and one consumer 
product company. 
Hi-tech Computer Vendor 
In early 1980，s when the open door policy began to be implemented, the PRC 
market had a hunger for high technology to expedite its rate of modernization. Up to 
now, technology is still in a great need. Those companies, like computer firms, which 
can provide advanced technology are considered to be beneficial to the country and 
are most welcome. 
On the other hand, the PRC market was very attractive to computer industry 
because the great potential as virginland in early 1980，s which promised high return 
on investment. Based on the recent performance, the PRC market really demonstrates 
exponential growth instead of a constant one from the developed countries like U.S. 
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and Europe. In the coming ten years，a double digit growth is still expected. 
Therefore, the computer vendor being interviewed established a wholly owned 
subsidiary in early 1980，s with great emphasis in the areas of sales and service. Its 
mission is to provide advanced technology that PRC cannot access as well as training 
so that high quality local staff can be developed to enable localization. 
One of the key successes of this computer vendor stems from its good relation 
with the PRC government which has been built up since the company entered the 
market. There are a lot of Joint Venture (JV) projects undertaken with various 
government ministries like Central Ministry of Agriculture, and key universities and 
institutes like Institute of Academy of Science in the development of software. Due 
to the characteristics of central planning economy, the government has the full 
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authority to allocate fund to technological investment. 
Since "Guang xi" is an important element in the PRC context which is the 
fundamental basis of all aspects of business negotiation, this computer vendor has 
already taken a very successful first step of strategic importance in its future 
development in PRC. Meanwhile, the company is now being invited to take part in 
the eighth Five Year Plan (FYP) which provides numerous golden opportunities to 
promote its products to help the PRC government materialize the four modernization. 
In addition, government policy of the country of origin in computer industry 
also plays an important role in shaping the competitiveness of a computer company 
in PRC. There was a rationale behind why companies, like IBM, selling mainframe 
computer products are less competitive in PRC. It was rooted in the restriction of the 
U.S. government in granting export license to mainframe computer products but not 
to mini-computers. This computer vendor which is strong in mini-computer 
networking capitalized on this competitive advantage to achieve early success in PRC. 
Even the restriction of exporting mainframe computer products may have been relaxed 
by now, these mainframe companies are still at a competitive disadvantage because 
their products are already outdated. 
With respect to other competitive forces, it was well understood that the 
bargaining power of buyers was the strongest in early 1980，s. In those days, the PRC 
economy was not prosperous enough to afford high priced products and customers 
were mainly ministries or institutes under government. Due to low affordable level 
and profile of customers, the prices of computers and related product packages were 
forced to drive down. 
Moreover, copyright protection was seldom respected by buyers. Illegal 
software copies were made available very extensively which caused a substantial loss 
in the company during the initial period. 
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Since the economy has been growing for the last decade so rapidly that high 
priced products are much easier to accept and there are more commercial firms 
established in PRC which are also in need of high technology support. On the other 
hand, buyers learn to respect copyright because they understand that copyright is a 
kind of intellectual property and it is more worthwhile developing newer software 
program based on the available ones rather than just copying the basic programs. 
These changes make the bargaining power of buyers less important. 
When year 2000 is approaching, the pressure has gradually shifted to threat 
of new entrants and industry rivalries in the PRC computer industry. Like automobile 
and home electric appliances, the competition from Japan is considered to be the 
greatest mainly because of the following reasons: 
. The concept of success in most Japanese companies focuses on market share 
rather than profitability which may have a risk of dumping with extremely low 
prices. 
. Japanese companies are very flexible in business strategies like extensive 
sponsorship which is very effective in building up "Guang xi". 
. There is high level contact between Chinese and Japanese governments which 
usually affects the decision making process for important business deals and more 
seriously affects the government policy in favor of computer firms of Japanese 
origin. 
In view of the future challenges, this computer vendor will take an approach 
of providing total solution to customers which builds on its company strength and 
fulfils the market needs. The company will offer hardware technology which requires 
integration to develop extensive network. Relevant training to ensure proper 
implementation and assistance in initiating program running will be provided as part 
of service package. 
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This strategy applies to both government and private sectors. On one hand, 
JV projects in the government sector should be enhanced to further strengthen the 
current customer base and on the other hand, the private sector has to be developed 
to cope with the exploding economic growth in the coming years. 
In this case, apart from the basic application of Porter's model, government 
policy is another important feature that should be included in order to account for the 
success of this computer vendor in the PRC market. In early 1980，s，its customers 
was confined to the PRC government which is the unique source of funding under the 
central planning economy system. Furthermore, the restriction of its competitors' 
exporting activities by the U.S. government also affected the competitive structure of 
the PRC computer market. Therefore, government policy was almost the commander 
of competition in the PRC computer industry. 
However, in Porter's model, government policy is only an indirect factor 
affecting the competition in the context of free market economy. In the PRC context, 
the government can directly interfere the economic activities in the market. Therefore, 
possible excessive influence by the government policy should be thoroughly evaluated 
in the formulation of competitive strategy in PRC if the role of the government is 
important in that particular industry. 
Consumer Product Company 
The 1.1 billion population and the booming economy have been attractive 
enough to consumer product manufacturers to make an imperative stake in PRC. PRC 
is the strategic market to foreign consumer product marketers in terms of profit 
generation and being successful as a major player in Asia in the coming decades. 
The reason is also very straight forward why PRC allows the entry of foreign 
consumer product firms even there are already a number of local producers. It is 
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because the standard of living is improving with economic growth. The need of 
consumers for products of higher quality and wider variety is increasing. 
The company being interviewed started a JV operation in PRC five years ago. 
The venture is formed among the company itself, a local soap factory in Guangzhou 
and a Hong Kong company which has had successful experience in penetrating into 
PRC Its global purpose of statement, to provide quality breakthrough products at 
reasonable prices, is also applied to the PRC market. Currently, there are a 
manufacturing plant situated in a city near to Guangzhou and regional sales offices in 
the key cities like Shanghai and Beijing. 
The key factors leading to the success of this consumer product company stem 
from the following strategic decisions: 
. Cooperate with a right local partner who is open-minded and is willing to share 
the same mission to ensure each step is a right move. 
. Establish the plant in the Southern China instead of the traditional commercial 
and industrial city, Shanghai, where its key competitor, Unilever, is based. 
. Offer key necessities product line, like shampoo and soap, to ensure fast initial 
market acceptance. 
Unlike hi-tech computer products, consumers products have lesser government 
interference and are competing as if in the free market economy which is the basis of 
Porter's model. Nevertheless, there is some uniqueness in the PRC consumer market 
which will, to a great extent, affect the strategic decision on top of the features 
highlighted in Porter's model. 
First of all, there is a great technological gap in consumer product 
manufacturing between developed countries in the western world and PRC which 
belongs to developing category. The general public's need is staying at a relatively 
primitive level. Secondly, the affordability level in PRC is still much lower than that 
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in advanced countries. There is no point to introduce those products far exceed the 
need of the majority of the people. Therefore, shampoo and soap are the product 
focus of this company in PRC. The overall economic and technological profile the 
targeted market is not included in Porter's model. 
Furthermore, the culture of the market in interest is not emphasized in the 
formulation of competitive strategy according to Porter's framework. Cultural 
differences may become a competitive force due to misunderstanding. Therefore, a 
local partner is of paramount importance in narrowing the cultural gap so that a sort 
of blending strategy satisfying the foreign company and local people can be 
developed. This is common for those industries in which local players have been 
fairly mature. 
Lessons from Case Studies 
Based on the two cases, the key points that should be noted when designing 
the competitive strategy for Merck in the PRC context are outlined as follows: 
i 
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. The direct effect of government policy in the industry. 
. The economic discrepancy between PRC and the country of the foreign firm. 
. The technological gap between local and foreign producers. 
. The cultural difference between the Chinese and the westerners. 
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CHAPTER III 
PHARMACEUTICAL INDUSTRY ANALYSIS 
This chapter will thoroughly analyse the pharmaceutical industry environment 
of PRC based on the five competitive forces of Porter's model. These forces include 
intensity of rivalry among existing competitors, threat of new entrants, threat of 
substitutes, bargaining power of buyers and bargaining of suppliers. The prime 
objective is to evaluate whether pharmaceutical is a five-star industry in PRC which 
is structurally attractive to Merck. 
Intensity of Rivalry Among Existing Competitors 
Rivalry among existing competitors takes the familiar form of jockeying for 
position — using tactics like price competition, product introduction, and advertising 
battles. Rivalry occurs because competitors either feel the pressure or see the 
opportunity to improve position. In most industries, firms are mutually dependent. 
According to Porter, intense rivalry is related to the presence of various factors. 
These rivalry determinants include: 
. Numerous or equally balanced competitors 
. Slow industry growth 
. High fixed or storage costs 
. Lack of differentiation or switching costs 
. Capacity augmented in large increments 
. Diverse competitors 
. High informational complexity 
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• High strategic corporate stakes 
. High exit barriers 
In the pharmaceutical industry of PRC, there are local and foreign firms 
competing in the marketplace. Local firms are usually active in production aspect 
while less involved in researching new products because of lack of technology. 
Coupled with the loose local patent law, copying compound developed in western 
countries through a different manufacturing pathway contributes the majority of 
business to these local firms. 
Foreign firms still reserve basic research of new products in the country of 
origin. Products can be made available to PRC market via the following 
arrangements: 
. Import finished which are directly imported with full or partial packing and ready 
for sale without any manufacturing procedure required in PRC. 
. License manufacturing which relies on a local partner to complete the formulation 
procedure by importing bulk materials. That the formulation plant of the local 
firm should be upgraded to the foreign company's standard is the basis of such 
business arrangement. 
. JV manufacturing which is a business alliance between foreign firm(s) and local 
firm(s). Each party shares an agreeable portion of the project through negotiation. 
The production requirement is similar to that of license manufacturing. The main 
differences are, firstly JV manufacturing allows the foreign company to report the 
in-market sales revenue in the financial statements and secondly the foreign 
company can directly influence the sales and marketing activities. 
Appendix III shows the profile of major foreign players. Since pharmaceutical 
R&D is much more advanced in the western countries, it is generally believed that 
foreign-researched pharmaceuticals are of high quality and efficacy than local ones. 
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Therefore, provided that the product is originated in advanced countries, it can 
command premium price. Furthermore, the level of technology used in production in 
PRC still lags behind the latest Western development (Swanson 1992). Those local 
brands with same generic components solely made by local plants are much cheaper 
than the original foreign brands made by JV or license manufacturing because the 
quality from the latter is expected higher. 
Broadly speaking, foreign and local pharmaceutical are competing in different 
segment. Appendix IV clearly illustrates that three generic strategic approaches for 
three types of products. Import finished pharmaceuticals are of the highest quality to 
justify high prices should be in the focus segment; foreign brands locally made by JV 
where quality can be guaranteed while manufacturing cost is very much reduced 
should be in the differentiation segment; local brands and generic copies are using 
overall cost leadership strategy. 
Number of Competitors 
Although there are numerous local pharmaceutical firms competing in the 
marketplace, it is expected that they cannot impose substantial threat on the foreign 
competitors unless new business arrangement, like JV or license manufacturing, is 
aligned because they are competing in different segments as analysed above. 
On the other hand, the US$100 million from Janssen constitutes less than 2% 
of the total medical expenditure on pharmaceuticals in 1991 which marked US$5.6 
billion. Concentration or domination has not appeared in the foreign pharmaceutical 
firm segment. 
Since the earliest JV project commenced in 1986，there have been more than 
ten similar projects laid down with different foreign pharmaceutical firms between 
1990 and 1992. A list of these projects are shown in Appendix VIII. Therefore, the 
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pharmaceutical market order in PRC has not yet established. 
The competition in PRC is considered to be fairly healthy in particular in the 
foreign-researched segment because the in-market prices approved by government are 
not subject to sudden increase or drop. Most foreign pharmaceutical firms are 
focusing on product promotion through various means to expand demand: 
In conclusion, to Merck as an new entrant, the existing competitive 
environment where vigorous retaliation by the existing market player is not expected 
is still favorable. 
Industry Growth 
PRC is the sixth largest pharmaceutical market in the world. Its 1991 sales 
was US$5.6 billion. The market has been growing at an average rate of 18% p.a. for 
the past five years. In the first trimester of 1992，it had 26% growth against the same 
period in 1991 which is largely contributed by the JV foreign companies. It was 
reported that the combined net profit reported by six JVs exceeded 20% of the entire 
industry (> US$55 million). 
Not only the existing market size of PRC is attractive, but the future market 
potential is exceedingly high because there is a huge population (800 million 
uninsured Chinese) who need better health care when the economic environment is 
progressively improving. 
With the expanding characteristics of the pharmaceutical market in PRC, it can 
provide substantial room for expansion which insures that existing firms can improve 
result just by keeping up with the industry and where all their financial and 
managerial resources may be consumed by expanding with the industry. 
Pharmaceutical firms in PRC are not required to steal sales from competitors 
as in those slow growing markets to achieve certain level of profitability. Again, 
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rapid industry growth is attractive. 
Fixed Costs 
The investment in the pharmaceutical sector can be regarded as high. Using 
the recent US investment in JV or licensing manufacturing projects as a guideline, the 
fixed costs range between US$1 and 35 million depending on the scale (Swanson 
1992). Careful analysis on breakeven is essential or the firms will expose to strong 
pressure to fill capacity which often lead to rapidly escalating price cutting when 
excess capacity is present. 
Because of the high risk of enormous investment, foreign pharmaceutical firms 
tend to go for JV or licensing arrangement instead of wholly owned subsidiary. Local 
partners can offer the following benefits: 
. Having basic facilities like power, water and simple equipment available, the 
investment in building the plant can be shared. 
. Providing local expertise who have established relationship with relevant 
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government bodies which can expedite the process of project negotiation. 
. Assisting foreign pharmaceutical firms in establishing a co-operative image rather 
than an invasive one because the competitiveness of local firms can be increased 
by upgrading their production technology. 
Differentiation Costs 
According to Porter, where the product is perceived as a commodity or near 
commodity, choice by buyers is largely based on price and pressure for intense price 
competition results. This applies to the market that generic products are copied by 
local firms in the pharmaceutical industry in PRC. 
Distinctive product differentiation is found between the foreign original brands, 
either in the form import finished or made by JV/licensee, and the locally made 
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generics. However, as discussed in the section of "Number of Competitors", they are 
not directly competing with each other. Instead they have their own target segment 
preferences which creates layers of insulation against competitive warfare. 
For foreign original products, due to the strong marketing effort is put behind 
by the firms in establishing their brands, doctors tend to be fairly loyal to a particular 
product which can in turn be translated into the differentiation cost. 
Diversity of Competitors 
Generally speaking, competitors diverse in strategies, origins, personalities and 
relationships to their parent companies have differing goals and differing strategies for 
how to compete and may continually run head on into each other in the process. The 
pharmaceutical competitors in PRC are becoming more diverse than ever since foreign 
investments started in mid-1980's. 
Nevertheless, the approach of these competitors, to a certain extent, can be 
anticipated because similar strategies may have been implemented in other markets. 
For instance, Japanese pharmaceutical firms usually introduce products at lower 
dosage strengths to cope with pricing strategy and utilize sponsorship as the main 
focus of the promotion mix. As the activities in the PRC market often lags behind 
those in other advanced countries, reactive or even proactive actions can timely be 
conducted to minimize the negative impacts if marketing staff is well sensitized. 
Strategic Corporate Stakes 
PRC is a promising market for pharmaceutical industry in the next several 
decades in the Pacific Rim because it has a deservedly high reputation among 
developing countries for providing quality health care. It can be demonstrated by the 
increased funding allocated for health care infrastructure and development during the 
Seventh and Eighth Five-Year Plan (FYP, 1986-95). During the 8th FYP，PRC hopes 
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to boost production in the medical industry by 8.5 percent annually, domestic sales are 
scheduled to increase by 7 percent per year (Swanson, 1992). For the entire 1991-
2000 period, ¥26 billion has beqn allocated by central authorities for investment in 
capital construction and technical upgrading in this sector (Swanson, 1992). 
It is not surprising that pharmaceutical firms, in particular those with foreign 
origin, have high stakes in achieving success. In order to ensure long term success, 
they might be willing to sacrifice short term profitability. Fortunately, the potential 
of PRC market is still large enough to accommodate every player to be a winner. 
Exit Barriers 
Generally speaking, the exit barriers for multinational pharmaceutical firms are 
quite high. The sources of barriers are identified as follows: 
. Manufacturing plants are highly specialized which often have low liquidation 
value. 
. High fixed costs of exits including labour agreement are involved. 
• Alliances are established with government run operations which involves 
discouragement of exit out of concerns for job loss. 
Threat of Entry 
Currently, Merck has not established any direct presence in PRC. The business 
is undertaken by exporting through a licensee which means that the products are made 
available as import finished. However, such an arrangement makes Merck's products 
extremely uncompetitive because the in-market prices are far beyond the affordability 
level in PRC. 
The current in-market prices of Merck's products are almost three times the 
ex-manufacturer prices because of the following factors: 
. Moderate profit margin offered to licensee 
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• Import duty set at 39% upon entry to PRC 
. High cost of foreign exchange due to the grey market exchange difference 
. High distribution margin charged by the three-tiered distribution system 
Therefore, Merck's current sales are exceptionally small when compared to 
other multinational pharmaceutical firms which have JV or licensing manufacturing 
established. In order to allow Merck to achieve a meaningful market share in the 
pharmaceutical market of PRC, Merck's products must be affordable by local Chinese. 
An entirely different operations has to be established to maximize Merck's strengths 
to facilitate its penetration in the PRC market. 
As discussed in the previous section of "Industry Growth", JV or license 
manufacturing is more preferred to wholly owned subsidiary. Furthermore, comparing 
JV and license manufacturing, the former should be more favorable because Merck 
can influence on the quality of sales and marketing and ensure the approach to be in 
line with the corporate policies. 
Although several products have already been on the market for some time, 
Merck is regarded as a new entrant to the PRC pharmaceutical market with respect 
to company as an entity. 
New entrants to an industry is generally believed to be negative by existing 
market players. It is because the prime desire of the new entrants is to gain market 
share by bringing new capacities. As a result, prices are usually driven down and 
costs are jerked up which lead to reduction of profitability. 
According to Porter, the threat of entry into an industry depends on the barriers 
to entry that are present, coupled with the reaction from existing competitors that the 
entrant can expect. If barriers are high and/or the newcomer can expect sharp 
retaliation from entrenched competitors, the threat of entry is low. 
The threat of entry of pharmaceutical industry in PRC is evaluated based upon 
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the major sources of barriers to entry defined by Porter. 
Government Policy 
Patent Law 
The characteristics of pharmaceutical industry is highly relied on extensive 
R&D which usually costs more than US$100 million for a particular product. Those 
new molecules eligible for marketing for human use are normally patented. For 
advanced countries like the United States and Hong Kong where patent protection for 
drug molecule and manufacturing process is well respected, secure return on 
investment is more promising. The degree of security is very much dependent on the 
extent of patent law enforcement. 
PRC belongs to another extreme of the patent protection continuum where only 
drug molecule is patented. If the same drug is manufactured through a different 
pathway, protection will not be valid. Branded pharmaceutical business is more risky 
in PRC. 
Although the patent regulation has been updated early this year with the 
introduction of the manufacturing process patent protection to the drugs that were first 
patented worldwide after January 1，1986 and have not been marketed in PRC before 
January 1，1993, the enforcement is very much doubted, in particular when corruption 
issue is involved. Nonetheless, it is regarded as a continuing improvement of 
intellectual property protection which will be a good opportunity for research-based 
pharmaceutical companies like Merck. 
Protectionism 
Although doctors in PRC generally prefer using import finished branded 
pharmaceuticals because of higher quality, the government has established barriers to 
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discourage import of finished products. This stems from both protectionism of the 
industry and control of health care cost. In 1991, US$11 billion was spent on medical 
expenditure which represented 3.9% GNP. US$4.2 billion of this amount was 
allocated to national health care scheme for the staff and workers working in 
government owned organizations and has increased six-fold in the past 11 years. 
Therefore, the government is concerned that only 17% of population has used up 38% 
of its medical expenditure. 
To keep a more balanced health care cost, the Expert Committee who is 
responsible for imported finished product registration exercises protectionism to 
various extent. It can refuse registration of a product if there are similar products 
available in China. In selected cities, patients are only reimbursed 50% for imported 
finished products but 90% for locally manufactured products. Due to the reduction 
of government subsidy, imported finished products impose a very significant financial 
burden on patients. 
Even when import finished products are not openly discouraged, the foreign 
manufacturer will be requested to undertake local production when the value of an 
imported item becomes significant, say more than US$10 million. 
Import Restriction 
The PRC government control over import licenses also significantly limits 
pharmaceutical imports. Currently, almost all pharmaceutical products must be 
imported through the Medicine and Health Product Import/Export Corporation 
(MEHECO), which fall under the auspices of State Pharmaceutical Administration 
(SPA). MEHECO，s approval is based on whether local alternatives are available in 
sufficient quantities to meet demand, and whether the imported drug is to be used to 
treat a priority disease in PRC. The criteria, in addition to quality and reliability 
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standards that also must be met, apply to both import finished and bulk preparations 
which have been formulated ready for tableting locally. Approved imports are 
assessed a 30-percent duty upon entry to the country. 
Imports of raw materials to be used in local pharmaceutical production 
generally fall under the jurisdiction of the Ministry of Chemical Industry, and 
therefore are subject to other import requirements. 
On a whole, the import policy is costly, complicated and time consuming 
which forms another barrier to new entrants who have not established working relation 
with the related government units. 
Local Manufacturing Policy 
Before the reforms of patent law which does not cover the manufacturing 
pathway, the PRC manufacturing policy grants great favoritism to local manufacturers. 
Every product can be produced locally as a generic by any manufacturer which is 
registered as the first manufacturer if the manufacturing process is different from that 
of the original drug researcher. It can even be marketed with the same tradename as 
the branded one. 
If the original drug researcher who is usually a foreign pharmaceutical 
company, needs to produce the drug in PRC as the second manufacturer, approval has 
to be obtained from the first manufacturer. Generally speaking, approval is less likely 
to be granted unless the product quality is significantly better than that of the existing 
one. 
However this policy did not apply to a situation that the first manufacturer is 
a foreign company while the subsequent manufacturer is a local company. As long 
as the generic product can demonstrate its bioequivalence to the branded one, 
manufacturing right can be granted. 
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This protection for local manufacturer sets a great barrier for the foreign 
pharmaceutical company which has no local manufacturing plants. 
Health Care System 
The sources of health care financing in PRC are extremely varied and complex. 
They include both direct and indirect government spending, different types of 
insurance plans and expenditure by industry, collectives, private practitioners, and 
. patients. 
Up until about a decade ago, provision of health care in China was offered 
primarily through communes, which provided free and preventive care to their 
members. With the disbanding of the commune system, health care is now paid for 
through several methods: 
. Government monies 
. Insurance 
. Patient fees 
Of the 1.1 billion population, only 300 million (26%) living and working in 
the urban cities are covered by national health insurance reimbursement scheme. The 
rest, 800 million, who virtually are all farmers living in the rural or remote territories 
are not eligible for any health care benefit. Their access to health services depends 
on their ability to pay. 
Currently, the government is planning to expand the health care benefit to a 
nationwide level which implies that 1.1 billion people will be recruited in the 
reimbursement scheme. The ultimate effect can either be positive or negative to the 
pharmaceutical industry. There is no doubt that if greater coverage is explored, the 
market size is significantly increased in terms of patient number. However, if the 
medical expenditure is not proportionately increased, the potential in dollar value will 
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remain unchanged. It will end up with stringent cost containment measures like those 
exercised in the European countries. 
In the past，the reimbursement scheme covers total cost of diagnosis and 
treatment regardless of the value. Recently, the first step of cost containment 
measures, copayment method, has been implemented which requires the patient is to 
pay a certain portion of the therapy. This will be a significant drawback for those 
high priced imported products from new entrants which have not established any 
manufacturing facilities in PRC. 
Registration Procedure 
Unlike consumer products, pharmaceutical products have to obtain registration 
before they can be marketed. One of the basic criteria to request registration review 
is to complete a registration trial which lasts between several months and over a year 
depending on the drug category. The substantial lead time not only imposes capital 
cost of entry but also gives established firms ample notice of impending entry and 
allows them to formulate retaliatory strategies. 
Although the size and growth of the PRC pharmaceutical market is enormous, 
the registration requirement is fairly a barrier to new entrants, in particular when they 
do not know who to contact to expedite the overall registration procedure legally. 
Economies of Scale 
Economies of scale can be found in various functional areas of pharmaceutical 
industry. The most obvious is manufacturing which is followed by sales and 
marketing as well as distribution. 
With respect to production, the drug manufacturing plant facilities, for instance 
sterile environment for those injectable products and anhydrous chamber for those 
water soluble products, should be very sophisticated to ensure the product quality. 
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Therefore, the initial setup cost is very great. The production plant is only justifiable 
when the market demand is substantial which allows the unit cost to maintain at 
reasonable level. Otherwise, the production will be at a great cost disadvantage and 
lose its competitiveness. In the case of pharmaceutical industry in PRC, this factor 
may even be more critical because the source of supply and the unique packaging with 
Chinese text have to be registered. The products cannot be imported if the stock is 
inadequate or exported if the stock is excessive. 
For sales and marketing, scale economies are found when several products are 
being promoted because costs can be shared. There is usually a basic capacity of 
sales and marketing required to manage one product which can be extended to some 
other products without any further increment in capacity. The sales force promotes 
different products instead of one to the same target audience during one visit which 
can have a better utilization of resources. 
Product Differentiation 
As analysed in the previous section on "Differentiation Costs", there is a strong 
brand identification for foreign researched product segment in PRC. Brand loyalties 
can be established over time because doctors' confidence in a particular brand is 
strengthened by accumulation of experience. Once it becomes a habit, change is not 
easy within a short period of time. 
This favorable condition, to a certain extent, may be complicated by the 
availability of generics substitutes which are legal under the past patent law. The 
doctors have to consider the affordability level of patients before deciding to use the 
branded product or its generic variants. 
Given that the new patent law is enforced which creates a more protective 
environment for foreign researched products in PRC，brand identification can be 
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further developed. Therefore, for a new entrant, high investment in building a brand 
name，though risky, is required to gain customers' acceptance. Therefore, innovative 
products which are in line with advanced therapeutic trend are much preferred as they 
can challenge the conventional approach in the management of diseases. The 
successful rate of building brand loyalty is higher. 
Capital Requirements 
Although production facilities accounting for the majority of capital investment 
which has been explained in the previous section on "Economies of Scale", it is 
referred to a condition that the product has already been marketed. One of the 
profound characteristics of pharmaceutical industry is that up-front capital requirement 
for R&D to develop a new product which is over US$ 100 million is significantly 
high and risky. 
Extensive investment for R&D is still in need at different stages of the product 
life until it becomes declining. The study results will sometimes lead to an expansion 
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of the product usage, for instance new claims and special types of patient. In the case 
of PRC, this type of R&D investment is one of the major barriers to entry. 
Besides significant financial burden created, R&D requires a very long time 
to develop a new product for human use which is usually more than ten years as well 
as to demonstrate certain long term beneficial effect of the product after launch. Time 
is also a valuable resource which builds another great barrier to new entrants. 
Switching Costs 
Switching costs can be classified into two categories. One is to switch to a 
product of the same therapeutic class or to an established class and the other one is 
to switch to a product of a new class which is usually referred to those innovative 
products. In general, the switching cost for the former one is not too high because 
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doctors only need to learn the minor differences of the therapeutic effect, dosage and 
administration frequency of the product in the interest. 
However, this will be entirely different if a breakthrough product is introduced. 
It require a series of education program to arouse doctors' interest in gradually 
increasing their acceptance to the new concept of treatment which subsequently 
translates into action. Obviously, extensive cost is involved to enhance market 
acceptance to the innovative products which explains the high switching costs. 
There is virtually no difference between PRC and worldwide markets with 
respect to this particular characteristics. Therefore the barrier to entry created by 
switching costs is fairly significant in PRC. 
Access to Distribution Channel 
In PRC, distribution of pharmaceutical products is controlled through a three-
tiered system managed by the China National Corporation of Medicine (CNCM). At 
the top of the ladder are national Level I stations in Beijing, Shanghai, Shenyang, 
Guangzhou, and Tianjin, which allocate products to Level 2 distributors at the 
provincial level, who in turn sell to Level 3 stations within the county or municipality. 
At each level, a State-determined price mark-up is allowed (Swanson，1992). 
Although there would be a few independent distribution networks emerging to 
become involved in this sector, it is likely that CNCM will maintain tight control over 
drug distribution in order to minimize the risks of drug abuse and improper 
distribution. Most local firms prefer to rely on this traditional distribution system in 
order to avoid transport and bureaucratic obstacles. Multinational pharmaceutical 
companies which sell imported finished products or operates through license 
manufacturing also tend to use the distribution network, as setting up one's own 
network requires a considerable cost in terms of staffing and assets. 
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Under this system, those products with high profit and consistent high sales 
volumes attract distributors' greatest attention. On the contrary, those new entrants 
where sales revenue is still uncertain are very difficult to get distributors' support. It 
will subsequently affect the consumption at customers' level. Firm may have to 
sacrifice a certain portion of profit margin initially to ensure a better distribution 
which directly affects the rate market penetration in PRC. 
In view of the distribution problem, multinational pharmaceutical companies 
which have set up JV operations usually attempt to market their products 
independently in key cities while relying on the above tiered system to reach rural 
areas. 
Therefore, access to distribution channel imposes relatively great barrier to 
entry in PRC where the territory is so ample that distribution is vitally important to 
the overall success of business strategy. 
Expected Retaliation 
Among the current giant population in PRC，there are already 100 million 
people aged 60 and up. Considering a rapidly aging population in the coming two 
decades, it can simply be interpreted that the demand for health care products will 
steadily increase. Coupled with increasing urbanization, it will result in a greater need 
for convenient and high quality western medicine than for traditional Chinese herbal 
medicine. 
Due to the strong economic growth and the expanding aging population which 
causes rapid industry growth, there is great ability for the industry to absorb new firms 
without depressing sales and financial performance of established firms. Therefore the 
expected retaliation in PRC will not be so massive as that in the western developed 
countries. 
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Pressure from Substitute Products 
By placing a ceiling on prices it can charge, substitute products limit the 
potential of an industry. Unless it can upgrade the quality of the product or 
differentiate it via marketing or other means, the industry will suffer in earnings and 
possibly in growth. 
Herbal medicines and acupuncture regarded as the essence of ancient Chinese 
culture and tradition can be considered to be the substitute products in pharmaceutical 
industry of western medicines. Although there are not much scientific proof on their 
mechanism of action, Chinese people are fairly receptive because of personal 
experience and out-of-the-mouth promotion from relatives and friends. 
Nevertheless, the pressure from substitute products in the PRC pharmaceutical 
industry is not exceedingly great because the trend of urbanization is progressing 
which favors scientifically proven medication rather than accumulation of experience. 
An obvious example is anti-infective products which include antibiotics and vaccines. 
To cure serious infection, rapid onset of readily available potent medicines is 
critically important to ensure fast and complete eradication of the bacteria in the body. 
Western antibiotics can serve this purpose through intravenous injection whereas 
Chinese herbal medicine or acupuncture cannot achieve such a therapeutic goal. 
Regarding vaccines which is a type of preventive medicines help the body to build up 
resistance to viral infection, they are in great demand for developing countries like 
PRC. There is no such a category in Chinese herbal medicine. 
Another example that can be quoted is drugs for chronic diseases like 
cardiovascular disorder. This kind of medicine is a life-long treatment. Western 
medicines have the advantage of being convenient because the patients do not need 
to prepare the medicine by themselves. This trend will become more prominent when 
urbanization continues. 
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Apart from the fundamental differences in the product attributes between 
Western and Chinese herbal medicines, the training provided by medical institutions 
is dominated by western medicine which is perceived to be more systematic and 
advanced. The development of western medicine is also much faster because of its 
strong commitment in R&D. 
Therefore, the threat of substitute products in the PRC pharmaceutical industry 
can be overcome by putting stronger emphasis on quality R&D and marketing. 
Bargaining Power of Buyers 
Generally speaking, buyers compete with the industry by forcing down prices, 
bargaining for higher quality products or more services, and playing competitors 
against each other - all at the expense of industry profitability. 
The power of each of the industry's important buyer group depends on a 
number of characteristics of its market situation and on the relative importance of its 
purchases from the industry compared with its overall business. 
Unlike in consumer industry, the ultimate end user who is the patient is not the 
decision maker to select which particular brand in the pharmaceutical industry. It is 
decided by medical professions including doctors and pharmacists as well as 
distributors and medical policy makers. In the PRC health care system, these people 
are playing different and important roles in the decision making process - which drug 
should be used. 
As discussed in the previous session about "Government Policy", it explains 
how the medical policy makers can block the availability of a drug at different levels 
like registration and import. Although they are not involved in any of the purchasing 
function, they have great influence on whether the constitutional buyers can get access 
to the products they want in PRC. 
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Even a drug can smoothly pass policy makers' stringent control in PRC, it has 
to go through two buyer levels before making itself available in hospitals. These are 
distributors and pharmacists who are responsible for keeping budget. According to 
the tiered distribution systems, distributors are the first line contact with 
manufacturers. They are responsible for placing orders to manufacturers and 
subsequently delivering goods based on orders received from individual hospitals. 
Pharmacists are responsible for deciding which drugs should be made available in the 
hospitals based on the budget allocated. 
As both distributors and pharmacists are accountable for financial balance of 
the assigned budget where they have to bear a risk of keeping excessive inventory if 
the demand is lower than expected, they own a certain degree of bargaining power on 
pharmaceutical manufacturer. In the case of distributors, they are reluctant to 
purchase high priced new products unless there is attractive margin or other benefits 
offered. For pharmacists, during the initial phase of open door policy when marketing 
was not well developed, it was not uncommon that they-could force doctors to use a 
particular product which marked high inventory in hospitals. It was because their 
knowledge might not be too primitive to differentiate the attributes of different 
products. They would make the decision based on the price but not considering value 
for money. 
When a pharmaceutical product is made available in a hospital, it can only be 
prescribed if doctors are capable of defining the disease through various diagnostic 
tools and determining treatment is required. 
At doctor's level, the bargaining power is usually not too violent because of 
the following two main reasons: 
. Doctors basically are not responsible for the control of drug expenditure. 
Therefore they are less concerned about the price. 
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• The performance of the product is very important to the quality of the treatment 
to patients. Price is of lower priority from doctors' perspective. 
Despite the presence of bargaining power at higher level of the purchasing 
system in PRC, it can still be manageable. It is believed that if open door policy 
keeps going, marketing effort can deliver more valuable relevant information to the 
individual parties involved in the pharmaceutical buying process to enable to make 
better decision with respect to product quality and value for money. 
Bargaining Power of Suppliers 
Suppliers can exert bargaining power over participants in an industry by 
threatening to raise prices or reduce the quality of purchased goods. Powerful 
suppliers can thereby squeeze profitability out of an industry unable to recover cost 
increase in its own prices. 
The supplier side is generally not a big issue in pharmaceutical industry 
worldwide as well as in PRC because the critical ingredient is manufactured internally 
through a secret process which is under the control of the company. The other 
components of the medicine are simple chemical compounds which are inexpensive, 
easily accessible and sold as commodity by chemical firms. The packaging 
component is made of traditional materials like paper, aluminium foil and plastic 
which can be sourced very easily without facing great pressure from the respective 
manufacturers. Instead, pharmaceutical firms have powerful bargain for those items. 
As a result, provided that the labour force of the manufacturing plant is well 
organized internally to get them functioning productively, the supplier pressure of 
pharmaceutical industry in PRC is not excessively powerful. 
Summary 
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To conclude, based on Porter's model, pharmaceutical industry in PRC is 
structurally attractive because: 
. Giant industry competitor has not appeared. 
• Threat of new entrant is fairly low. 
• Threat of substitute products is not great. 
• Bargaining power of buyers, though strong, is manageable. 
• Bargaining power of supplier is very small. 
These five key competitive forces are diagrammed in Appendix V which shows 




Following the industry analysis in the previous chapter, it is concluded that 
PRC pharmaceutical industry is highly profitable because, to a very great extent, the 
five determinants favor profitability. 
However, Merck officially started the business in PRC by exporting through 
a licensee in 1989 which has already lagged behind those pioneered companies, like 
Janssen, Squibb and Smith-Kline-Beecham for almost half a decade. The licensing 
partner was a technoventure company with no expertise knowledge in PRC 
pharmaceutical business. Since the licensing agreement would only last for five years, 
it appeared that the licensee was not willing to make long term commitment. For 
instance, it has not tried to build up a well-organised structure which caused staff 
responsibility overlapping and decision making process ineffective. 
In addition, pharmaceutical promotion belongs to high-manpower involved 
type. The knowledge of sales force is vitally important to ensure product information 
is correctly conveyed in a balanced perspective manner as well as in line with product 
strategy. However, the licensee has not paid much attention to developing sales 
force's communication skill in product promotion. 
Furthermore, as explained in the section of "Threat of Entry" in Chapter III， 
the in-market prices of some Merck's products are virtually uncompetitive in PRC. 
One might imagine how extreme the situation is that the daily costs of certain 
products are more expensive than those in the U.S.. For those life-saving products 
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and the course of therapy is limited five to seven day, like injectable antibiotics, there 
is still market in that particular segment. However, for those life-long treatment, like 
cholesterol reducing drug, the opportunity of getting share is very slim. 
The above are the main reasons why Merck has not made any great 
achievement, especially with respect to sales revenue, in PRC so far. Judging from 
this situation, it is almost impossible for Merck to capitalize on the attractiveness of 
the PRC pharmaceutical industry with the current business arrangement. 
Therefore, in this chapter, it will discuss how Merck can become a successful 
player in PRC. To accomplish the goal, a competitive strategy should be developed 
to enable Merck to cope successfully with the five competitive forces and thereby 
yield a superior return on investment. 
Those key challenges faced by Merck are summarised as follows: 
• Compared to the existing JV pharmaceutical operations in PRC, Merck is a new 
entrant in PRC. How Merck catches up and outcompetes them within the shortest 
period of time? 
. A full range of Merck's product line consists of more than 50 products globally. 
How Merck manages the product portfolio to ensure fast penetration while 
minimizing generic replacement in PRC? 
Entry Strategy 
The possible alternatives of entry strategy are including: 
. Wholly Owned Subsidiary 
. Joint Venture Organization 
. Licensing 
. Exporting 
Wholly Owned Subsidiary 
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If 100 percent ownership is pursued, Merck has a significant advantage of 
avoiding any potential problems of communication and conflict of interest that may 
arise with the involvement of a partner. Full line of operations including local 
manufacturing and marketing is implemented. However, the time and energy required 
to attain such organization seems to be unrealistic that we can catch up the leading 
competitors in the next ten years. Although full ownership is highly favorable in 
terms of control, there is a great drawback in competition if time factor is considered. 
Joint Venture Organization 
This form of organization which involves the partnership with a local 
pharmaceutical firm are most welcome by multinational pharmaceutical companies as 
shown in Appendices III and VI. The advantages of this strategy are the sharing of 
risk and the ability to combine strength in a joint venture. 
Since Merck lacks of in-depth knowledge of the PRC pharmaceutical market 
but has considerable R&D and human resources backup, the local pharmaceutical firm 
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should possess the following strengths so as to achieve maximum synergy: 
. Have established relation with policy-makers to minimize the negative impact an 
Merck's products. 
. Have fairly large scale manufacturing plant to enable local production right from 
the start. 
. Have extensive sales force coverage to implement direct product promotion to 
doctors and pharmacists. 
. Have good rapport with distributors and pharmacists to ensure adequate supply 
of Merck's products to hospitals. 
• Have the same mission shared with Merck -- to provide effective medicines for 
• the most serious and costly diseases in PRC. 
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The main disadvantage of joint venturing is the very significant costs of control 
and co-ordination associated with working with the local pharmaceutical partner. 
Licensing 
Licensing is also an alternative with considerable appeal. Through licensing 
agreement with a local pharmaceutical firm, Merck's products can be produced locally 
and marketed with minimal investment and expenses by importing bulk or 
manufactured formula materials. The profile of the local partner should be similar to 
that described in the previous section on "Joint Venture Organization". The only 
difference from the current arrangement is that local manufacturing will be pursued 
to address the pricing issue. 
The principal disadvantage of this licensing approach in PRC is that Merck will 
lose control over the quality of marketing which is a key determinant of the success 
of a new product. The potential returns will then be affected. 
Exporting 
Similar to the current situation, products are manufactured abroad and sold as 
import finished in PRC. The advantages of exporting are that it allows Merck's 
manufacturing operations to be concentrated in a few locations to make co-ordination 
and quality control easier. This is especially true if the demand in each market is still 
very small in which decentralized manufacturing is not justified, or production line is 
unique and cannot share with other products. 
Although investment in manufacturing operation is not required, marketing 
effort is directed by a JV operations to gain the maximum advantages from PRC 
pharmaceutical firm's market expertise and Merck's investment in R&D and 
marketing know-how. 
The unaffordable pricing issue left unresolved is the obvious shortcoming of 
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this form of business arrangement. From the economic point of view, Merck may 
entirely lose its competitiveness to other players. 
Portfolio Strategy 
In the PRC context, Merck's products can be classified in the following 
categories: 
. Fully patented in PRC 
. . Unpatented in PRC but patented in advanced countries 
. Unpatented on a global basis 
Fully Patented in PRC 
There are two types of protection granted depending on the status of worldwide 
patent，and that of local registration and marketing situations. For those products 
which are patented in foreign countries after January 1st 1993, there will be 20 years 
protection. For products which were patented between January 1st 1986 and 
December 1st 1993，and have not been registered or marketed in PRC, there will be 
seven and a half years pipeline protection. 
These products are the newest entities along the product line and have better 
therapeutic performance than existing products. Therefore, to capitalize on the 
competitive advantage for patent protection, Merck should pursue differentiation 
strategy to command premium prices to attain high returns. 
Compared to Janssen which is the current leading multinational pharmaceutical 
company, Merck has an exceptionally stronger research pipeline with a number of 
products in late-phase clinical studies. This is a sustained advantage for Merck to 
successfully compete with Janssen in the long term run, say five to ten years. 
In addition to a correct strategic advantage, right strategic target is also crucial 
to the success of Merck's PRC patented products. Although the PRC economy is 
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expanding very fast, there is a great discrepancy in affordability between urbanized 
cities and rural districts. The urbanized cities are less vulnerable to the restriction of 
reimbursement policy because patients are more able to pay even the drug costs are 
not fully reimbursable. Moreover, educational level of both doctors and public is 
generally higher, and information flow is more efficient in the urbanized cities. 
Therefore, a focus approach for Merck's PRC patented products is more justifiable at 
least for the first five years with intense marketing effort to establish the brand. 
Gradual shift to a broader target base can be considered when approaching to the era 
of 2000. 
Unpatented in PRC but Patented in Advanced Countries 
This group of products are usually either the star or problem children in the 
worldwide markets according to Boston Consulting Group analysis. They have 
significant competitive product advantages over the old product which no longer or 
almost do not have patent protection. 
In order to maximize the potential of this group of products, broad 
differentiation strategy should be adopted. On one hand aggressive marketing effort 
is utilized to establish the brand image, on the other hand affordable price is adopted 
to allow broad target coverage. Although these products are subject to substantial risk 
of generic erosion, local manufacturing partnership arrangement will impose certain 
barrier to generic entry because guaranteed product quality can defend the slightly 
premium price. 
The strategy will become more complex if Merck has more than one brand 
with minor product differences treating the same kind of disease. In order to fully 
maximize the potential of individual brands, dual strategy should be pursued. The 
same broad differentiation strategy can be applied to certain brands with Merck's 
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participation in local manufacturing and marketing. Broad cost strategy will 
simultaneously be designed for some other brands via licensing. Of the two strategies, 
the price of the latter one is expected to be lower because it is generally believed that 
marketing programs initiated by local pharmaceutical firms are less sophisticated in 
creating an outstanding intangible brand image. 
Although Merck has no direct control over marketing operations for the latter 
strategy to add value to the products, it is an advantage from the resources 
management point of view because limited resources is a realistic concern in the 
world. 
This series of products will create head-on competition with the top ten 
multinational pharmaceutical companies in PRC, like Squibb, Smith-Kline-Beecham, 
and Glaxo etc, especially when similar product class is present in competitors' product 
line. Merck should also successfully compete in this category by its consistent and 
creative marketing effort, and by licensing to good partners to maximize the total 
returns. 
Unpatented on a Worldwide Basis 
This product category are basically the older brands which were researched 
decades ago. Due to their long term availability worldwide, all the efficacy and side 
effects have already been established and are well known to doctors because they 
might have learnt the drug from basic medical textbooks. They might also play an 
important role in contributing to Merck's success with respect to generating profit in 
the PRC market. 
Since almost all doctors are familiar with these drugs, heavy marketing 
programs are not needed. If reasonably low prices which still allow Merck to make 
profit are offered, the profit is still very attractive when ample sales volume is 
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achieved. 
As these products are not protected by patent and may have had many copies 
in the market. In order to compete with the generic market, cost leadership strategy 
should be implemented. Skimming price strategy can be offered with an highlight on 
quality guaranteed by the original researchers as the promotion platform. 
Besides, the group of products also require broad coverage because both 
urbanized cities and rural territories are their targets which can enhance the benefits 
of economies of scale resulted from large sales volume. Broadly speaking, a broad 
cost strategy is appropriate for products without worldwide patent. Therefore, Merck 
is fuelled by further competitive advantages through licensing when compared to local 
and medium sized multinational pharmaceutical firms. 
Targeting Strategy 
Substantial economic gaps not only appear between PRC and the U.S. but 
among different cities or provinces within PRC., this makes nationwide promotional 
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approach as practised in the U.S. pharmaceutical market almost impossible. In order 
to justify the investment in the PRC pharmaceutical market, Merck should develop a 
precise targeting strategy based on careful market segmentation. 
The level of spending power of pharmaceuticals can be a relevant index to be 
based on to exercise segmentation. Such level is closely related to the degree of 
economic activity and health care subsidy. These are representing the total 
affordability of two parties, with the former from patients' pocket and the latter from 
the government or insurance. The combination of the two sources presents a 
continuum of the following four market segments which are also diagrammatically 
illustrated in Appendix VII: 
： High economic activity and good health care subsidy 
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• High economic activity and poor health care subsidy 
. Low economic activity and good health care subsidy 
. Low economic activity and poor health care subsidy 
High Economic Activity & Good Health Care Subsidy 
This segment can be referred to people working for enterprises in those coastal 
cities and Special Economic Zones which include Guangzhou, Shanghai, Beijing and 
Tianjin. These areas are being more urbanised with high GDP per capita. Costs of 
medical care are at least partially covered by insurance scheme. Due to high 
affordability, there is great potential for premium priced pharmaceuticals of superior 
quality. It is the key target for new advanced medicines where differentiation strategy 
is applicable. 
High Economic Activity & Poor Health Care Subsidy 
This segment only arouse after the implementation of open door policy, 
especially, in recent years people are encouraged to start up small business on their 
own by granting attractive tax exemption. Geographically, it also focuses on coastal 
cities and Special Economic Zones. 
Since these people are no longer working in the government or enterprises, 
they are not eligible for any of the current national health insurance schemes. 
Nevertheless, being self-employed, they can earn a lot more than before. The 
affordability level is still very high. Therefore new advanced medication is also 
applicable to this segment. 
Low Economic Activity & Good Health Care Subsidy 
This segment signifies the characteristics of those secondary developing cities, 
like Taiyuan, Wuhan and Changchun etc, which are a bit away from the primary ones. 
46 
The economic activity is obviously less flourishing. However, heavy industries there 
still provide substantial job opportunities for local people. In other words, the people 
belong to the insured group with various extent of medical coverage. 
Compared to the previous two segments, the potential for Merck's 
breakthrough advanced pharmaceuticals might be lower because both employers and 
people are less affordable to pay the premium. The potential tends to stretch to the 
low-priced end. 
Low Economic Activity & Poor Health Care Subsidy 
This segment is basically referred to uninsured people living in rural areas. 
Most of them are farmers. Their situation is the worst among the four segments. 
There is neither no way for people to generate money through economic activities nor 
no medical insurance coverage provided by employers. With such poor affordability, 
potential for Merck's products may be found in the very low-priced and unpatented 
ones. 
The above situation is expected to improve if the insurance is extended to a 
nationwide coverage in the coming years. By that time, this segment will gradually 
merge into the Low Economic Activity and Good Health Care Subsidy group. 
Alliance Strategy 
As identified in the case study in Chapter II，narrowing the technological gap 
between Merck and local partners is another challenge. It is discussed in the section 
of "Entry Strategy" that there will be two main types of local partners, namely, JV and 
licensing with whom Merck has to cooperate. An alliance strategy with respect to 
production in pharmaceutical industry is composed of various major steps in the 
process of establishing long term partnership along with the growth of Merck's 






Partner starts with toll manufacturing which is the simplest form of production. 
It only involves tableting of formulated powder imported from Merck's plant in the 
U.S. or overseas. No special expertise knowledge is required. 
Blending 
Partner is upgraded to handle the blending of the active ingredient supplied as 
bulk from Merck's plant in advanced countries and inactive components sourced or 
produced locally. Some expertise knowledge is involved in the blending procedure 
which is then followed by tableting again. 
Synthesizing 
Partner gets involved in synthesizing the secrete formula of the active 
ingredient. It is the most complicated procedure which may include fermentation and 
chemical synthesis. Blending and tableting are the subsequent steps to complete the 
full manufacturing process. Needless to say, extra high expertise knowledge is 
compulsory to ensure high quality and zero defect. Therefore, large scale technology 
transfer is essential. 
If the product is presented in injectable formulation, for example injectable 
antibiotics and vaccines, sterilization during bottling is an important manufacturing 
procedure. Again, high technology is required. 
The progress of upgrading local partners' production expertise along the above 
stages is dependent on various key factors which are: 
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• Reliability of partner 
. Overall corporate profitability of Merck 
. Readiness of partner 
• Requirement of government policy 
Among the above four，there is a fundamental difference in the partnership 
alignment between JV and licensing that causes the factor of reliability to be almost 
unnegotiable in the latter case. As Merck does not have any direct control over the 
licensee, the trust in the highly confidential matter is still very much in doubt. 
Therefore, if the partnership is made through licensing, the synthesizing step of 
production may never be reached. 
Apart from addressing the issue of technology gap, alliance strategy can also 
effectively deal with difficult situations caused by cultural differences. For instance, 
seniority counts on age in the Chinese culture which means that the older the person, 
the greater the power, the more the honour. However, it is entirely a cultural shock 
to American. Therefore, local partner, in particular, in the case of JV, can serve as 
a bridge between the customers in PRC and Merck's management to expedite their 





In order to expedite Merck's penetration in the PRC pharmaceutical market, 
the strategy should be multi-faceted to allow concurrent business development 
provided adequate resources are available. Appendix VIII and IX outline the matrix 
of entry strategy and portfolio strategy, and targeting strategy and portfolio strategy 
in the management of Merck's products in PRC. 
It is not impossible that Merck's full product line can be introduced to the PRC 
market by adopting different competitive strategies. Firstly, focus differentiation 
strategy is appropriate for PRC patented products with marketing function directed by 
JV operations, and products being produced either locally or abroad. Secondly, broad 
differentiation strategy is suitable for PRC unpatented but worldwide patented 
products. The JV operations is fully responsible for manufacturing and marketing. 
Thirdly, if there are more than one PRC unpatented but worldwide patented products 
available, broad cost strategy is an alternative option to fully maximize the product 
potential with minimal investment through licensing. On the whole, the profit is also 
fairly attractive. Finally, it comes the broad cost strategy for those worldwide 
unpatented products. Again, through licensing, superior profit can be attained if their 
volume is huge enough. 
Although it would be the best if all the above could start at one time, 
resources, in terms of time, finance and manpower, are limited in an actual 
environment. Therefore, the highest priority should be made to PRC patented products 
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which guarantee return on investment the most. The second priority should then be 
placed on the PRC unpatented but worldwide patented products because of their 
promotional responsive nature. Superior return can be created by outstanding 
marketing programs. 
In addition to financial return, Merck's research oriented corporate image can 
b e established through the promotion of these two groups of product. This can be 
regarded as a process of building up the confidence of doctors and pharmacists in 
Merck's advanced treatment technology which can subsequently help reduce the 
barrier of acceptance if new products are introduced in the future. 
Besides, product group focus is also different in different market segments 
defined in the section of "Targeting Strategy" in Chapter IV in order to maximize the 
potential for the product group as well as the market. Since high economic activity 
can lead to wealth for the majority of the people, the spending power is less dependent 
on the degree of health care subsidy. Therefore, for the two segments with the 
common characteristic of high economic activity, they belong to the highly affordable 
group, PRC patented products and PRC unpatented products supported by 
differentiation strategy are the key focus for Merck. 
However, if economic activity is low, the level of health care subsidy will 
become significant. For the worst case where subsidy is poor, the affordability is 
greatly bounded by the low income of rural farmers. Thus, the product group is only 
confined to worldwide unpatented products offered with very low prices. If health 
care subsidy is supported by employers as in those secondary developing cities, the 
product focus may stretch to PRC unpatented category with cost leadership strategy. 
As of today, the extensive investment made by all major multinational 
pharmaceutical companies are undertaken through JV arrangement. One of the 
important steps in forming JV is to identify an appropriate partner. The criteria of 
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selection has been discussed in the section of "JV organization" in Chapter III. In the 
process of screening, only those leading capable ones will be selected. With the 
combined strengths of foreign and local firms, those newly formed JV companies will 
favorably compete in the market and further expand. However, those sub-standard 
local ones will continue to lose their competitiveness and disappear ultimately. 
Therefore, in the long term run, say twenty years from now, the PRC pharmaceutical 
market may be dominated by successful JV companies. 
As the market environment is changing invariably, the set of strategy 
established at this stage should be evaluated and fine-tuned on a regular basis to 
ensure that strategy formulation and implementation are evolved with the market 
dynamism. This is the essence of crafting strategy (Mintzberg 1992) which 
emphasizes the ongoing nature of the process rather than a one-time off exercise. 
During the course of planning period, it is speculated that the following possible 
changes might take place in the marketplace in the next decade: 
. Rivalry among market players will become progressively intense as a result of 
substantial investment by multinational pharmaceutical companies in recent years. 
. Double digit growth in the PRC pharmaceutical market can be maintained which 
implies that the market will expand at least by three-fold by the year of 2003. 
This optimistic view is derived from the rapid economic growth and the 
implementation of nationwide insurance schemes. The affordability of the four 
market segments defined in the section of "Targeting Strategy" will be upgraded 
to accept better health care products more readily. 
. It may lead to a negative impact if insurance benefit is expanded to nationwide 
level because cost-containment issue may become more stringent. Price pressure 
from buyers, in particular government and insurers will increase. 
. The investment may become more justifiable as intellectual property will be more 
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secure after reforms of patent and trademark law. On one hand it can cause the 
industry more attractive, on the other hand competition will become more fierce 
as companies tend to increase investment to attain a better position in the market. 
Since changes can either be positive or negative, in order for Merck to be a 
major player in the PRC pharmaceutical market, it should play an active role in 
shaping the industry to more favorable for returns on investment. Although Merck is 
relatively late compared to its major worldwide competitors with respect to entry to 
PRC, with its strong commitment and highly co-ordinated implementation of the 
multi-faceted strategy, the objective of Merck to be successfully compete in the 
marketplace can still be achievable. Subsequent to the formulation of the broad 
competitive strategy, there is a series of ongoing challenges that has to be resolved. 
Some of them are listed as follow for careful consideration: 
• What is the most optimal infrastructure of the JV organization? 
• How to set up a regulatory body to ensure all market players are implementing 
ethical promotion? 
. How to improve the distribution channel to expand the number of outlets? 
• How to improve the management skill of different types of employee to increase 
productivity? 
All in all, strategic planning of Merck in the PRC pharmaceutical industry is 
a long term survival strategy for the overall corporate. 
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APPENDIX I 
COMPARISON OF HIGH- AND LOW- CONTEXT CULTURES 
Factors/ 
Dimensions High Context Low Context 
Lawyers Less important Very important 
A person's word Is one's bond Is not to be relied 
upon, "get it in writing" 
Responsibility for Taken by highest level Pushed to lowest level 
organizational error 
Space People breathe on each People carry a bubble 
other of private space with 
them and resent 
intrusions 
Time Polychronic - Monochronic -
everything in life must time is money 
be dealt with in terms Linear -
of its own time one thing at a time 
Negotiations Are lengthy - a major Proceed quickly 
purpose is to allow the 
parties to get to know 
each other 
Competitive bidding Infrequent Common 
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APPENDIX II 





— Jockeying for 
Bargaining power position among Bargaining power of 
of suppliers current customers 
competitors 
个 
Threat of substitute . 
products or services 
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APPENDIX III 
FOREIGN PHARMACEUTICAL COMPANIES IN PRC 
ACHIEVING MORE US$10 MILLION SALES IN 1991 
Country Operations 1991 
C o m P a n y of Origin (Year) j^VuSSmil� 
I. JV Operations Established before 1992 
Xian-Janssen Pharm. Corporation Belgium JV Mfg. (1989) 120 
Tianjin-SKB Pharm. Corporation U.S. JV Mfg. (1986) 82 
Shanghai-Squibb Pharm. Corporation U.S. JV Mfg. (1987) 78 
Sino-Swedish Pharm. Corporation Sweden JV Mfg. (1988) 30 
II. JV/licensee Operations Established in 1992 or after 
Takeda/Meiji/Yamanouchi Japan Import Bulk 100 
Shanghai No. 2 Pharm. Corporation Sweden Import Finished 11 
License Mfg. (1992) 





Broad Broad Broad 
(Industrywide) Cost Differentiation 




Narrow Cost Differentiation 
(Particular (import finished 
segment only) foreign brands) 
Low Cost Differentiation 
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APPENDIX V 
SUMMARY OF THE PHARMACEUTICAL INDUSTRY ANALYSIS 
• 
POTENTIAL ENTRANTS 
+ Government Policy 
+ Economies of scale 
+/- Product differentiation 
+ Capital requirements 
+/- Switching costs 
+ Access to distribution 
+ Expected retaliation 
• 
* INDUSTRY i 
SUPPLIERS COMPETITORS BUYERS 
+ Differentiation of inputs + Industry growth +/- Bargaining leverage 
+ Presence of substitution - Fixed costs - Buyer volume 
inputs +/- Differentiation cost + Impact on quality 
+ Threat of forward integration 0 Diversity of competitors performance 
relative to threat of + Corporate stakes +/- Price sensitivity 
backward integration by firms + Exit barriers +/- Brand identity 




- Relative price performance 
of substitutes 
+ Switching costs 
+ Buyer propensity to substitute 
Key: + = Make industry more attractive 
-=Make industry less attractive 
0 = Neutral to industry 
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APPENDIX VI 
JOINT VENTURE/LICENSING PHARMACEUTICAL PROJECTS 1990-92 
Company Project Completed bv 
Dalian Pfizer Pharm. Corp. Formulation plant end 91 
Hua Ming Pharm. Corp. Aramycin subdivision May 90 
Guangzhou Guanghua Pharm. Corp. External Contraceptive Mar 90 
Xinan Pharm. Corp. Cephalexin lysphilize end 91 
and subdivision 
Nanjing No. 2 Pharm. Corp. Oral Contraceptive Sep 90 
Shanghai No. 2 Pharm. Corp. License Mfg. of Madopar 1992 
Guilin-Yamanouchi Pharm. Corp. Famotidine tablet Jul 91 
Chongqing-Glaxo Pharm. Corp. Ventolin Nov 91 
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APPENDIX VII 
GEOGRAPHICAL ALLOCATION OF MARKET SEGMENTS 
BASED ON ECONOMIC ACTIVITY AND HEALTH CARE SUBSIDY 
a 
Key: 4r Coastal cities & Special Economic Zones (Shenzhen, Shanghai, Guangzhou, 
Beijing, Tianjin) : High economic activity and low health care activity 
South/North: High economic activity and high health care subsidy 
North East: Low economic activity and high health care subsidy 
West/South West: Low economic activity and low health care subsidy 
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APPENDIX VIII 
MATRIX OF ENTRY STRATEGY AND PORTFOLIO STRATEGY 
Patented in PRC Unpatented in Unpatented 
PRC worldwide 
JV operations Focus Broad __ 
Differentiation* Differentiation" 
Licensing -- Broad Cost" Broad Cost" 
Exporting Focus - .. 
Differentiation … 
Key: ‘ Responsible for manufacturing and marketing, or marketing only 
Fully responsible for manufacturing and marketing 
… Product manufactured abroad but marketed by JV 
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APPENDIX IX 
MATRIX OF TARGETING STRATEGY AND PORTFOLIO STRATEGY 
Economic Activity Hi Hi Lo Lo 
Health Care Subsidy Hi Lo Hi Lo 
Patented in PRC • • .. .. 
Unpatented in PRC • • • __ 
Unpatented worldwide — „ * • 
Key: • Appropriate strategy to maximize the potential of the market segment 
and the specific group of products. 
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